MedTrace Logo

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

NCT07080931 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2026-03-05

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

Conditions

Interventions

DRUG

5% minoxidil foam

Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

DRUG

Placebo for 5% Minoxidil Foam

Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

Sponsors & Collaborators

  • Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080931 on ClinicalTrials.gov